Source: FirstWord Pharma

Active Biotech: Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage

Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab...

Read full article »
Annual Revenue
$ < 1M
Employees
17
Tomas Leanderson's photo - President & CEO of Active Biotech

President & CEO

Tomas Leanderson

CEO Approval Rating

69/100

Read more